alm2....
I have read the information....There are a very few diseases which target the small blood vessels..But one of them is Scleroderma. Scleroderma is thought by most people including clinicians to be a skin disorder, but in reality Scleroderma is an inflammatory disease which effects the arterioles (the small arteries). Scleroderma effects most of the body..because of the general increase of inflammation in small arteries..In this sense COVID-19 might have similar, but, more more dramatic effects..In the clinical trial of one patient with Scleroderma that I treated with Vascepa..The clinical response was very dramatic..The patient had very limited range of motion..And required "devices" to put on her shoes or socks..Her gait was unstable and she was unable to walk without a stabilizer.
After a month on Vascepa she showed dramatic improvement in flexibility and mobility..Her GI system was better..I have not followed up on the Scleroderma boards..This was six or seven years ago..I have not followed up with the patient..(I am retired).
This is interesting, but is only anecdotal and does not provide any proof that V would work in a more acute situation..But it is a tantalizing tidbit...And I would not be surprised if Vascepa did provide some therapeutic benefit in COVID-19...And yes it could be fairly dramatic. Probably more effective if EPA is given very early in the disease rather than in end stage..Not sure where statins come in, but throw in the kitchen sink..
":>) JL
News 
Market Data 
Discover 
